{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016235","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.533210+00:00","generated_at":"2026-06-10T04:36:05.385974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MaxCyte preliminary Q3 revenue $7.8-8.0M; cuts FY2023 revenue guidance to $34-36M","bullets":["Q3 total revenue expected $7.8-8.0M, down 25-27% YoY; core revenue $6.4-6.6M, down 33-35% YoY.","FY2023 total revenue guidance reduced to ~$34-36M; core revenue guidance lowered to $28-30M.","SPL program-related revenue Q3 $1.4M vs $0.8M YoY; full-year SPL guidance unchanged at ~$6M.","Company cites depressed cell and gene therapy funding, customer inventory, and elongation of preclinical activity.","Ending cash expected ~$200M, unchanged from initial 2023 outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016235","json":"https://secwatch.observer/filing/0001558370-23-016235.json","markdown":"https://secwatch.observer/filing/0001558370-23-016235.md","text":"https://secwatch.observer/filing/0001558370-23-016235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023016235/0001558370-23-016235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023016235/mxct-20231004x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:36:05.385974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"649894f632683a5ecfd420df22a20014aa179f25","claim":"MAXCYTE, INC. reported the quarter ended September 30, 2023 results: revenue $7.8 – 8.0 million. Guidance reaffirmed.","evidence_excerpt":"preliminary revenue for the third quarter ended September 30, 2023 and updated its full year 2023 revenue guidance. ​ Preliminary Third Quarter 2023 Revenue · Total revenue of $7.8 – 8.0 million in the third quarter of 2023, a decrease of 25 -27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector. ·","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023016235/0001558370-23-016235-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$7.8 – 8.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}